# Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma

> **NCT05729646** · PHASE2 · RECRUITING · sponsor: **Yu jiren** · enrollment: 90 (estimated)

## Conditions studied

- Adenocarcinoma of the Stomach
- Adenocarcinoma of Esophagogastric Junction
- Mismatch Repair Deficiency

## Interventions

- **DRUG:** Toripalimab
- **DRUG:** Oxaliplatin
- **DRUG:** S1

## Key facts

- **NCT ID:** NCT05729646
- **Lead sponsor:** Yu jiren
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-31
- **Primary completion:** 2026-02-28
- **Final completion:** 2029-02-28
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2023-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05729646

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05729646, "Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05729646. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*